Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter, open label, nonrandomized study to evaluate the efficacy and
safety of lenalidomide at a dose of 10 mg/dose in combination with bortezomib at 1.0
mg/m2/dose, pegylated liposomal doxorubicin (PLD) at 4.0 mg/m2/dose, and intravenous (IV)
dexamethasone at 40 mg/dose in adult patients with relapsed/refractory multiple myeloma (MM).
The study consists of a screening period, followed by up to eight 28 day open label treatment
cycles, a final assessment to occur 28 days after the end of the last treatment cycle, and a
follow-up period.